<SEC-DOCUMENT>0001104659-20-030812.txt : 20200309
<SEC-HEADER>0001104659-20-030812.hdr.sgml : 20200309
<ACCEPTANCE-DATETIME>20200309165036
ACCESSION NUMBER:		0001104659-20-030812
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20200309
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200309
DATE AS OF CHANGE:		20200309

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOANALYTICAL SYSTEMS INC
		CENTRAL INDEX KEY:			0000720154
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				351345024
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23357
		FILM NUMBER:		20698562

	BUSINESS ADDRESS:	
		STREET 1:		2701 KENT AVE
		CITY:			WEST LAFAYETT
		STATE:			IN
		ZIP:			47906-1382
		BUSINESS PHONE:		3174634527

	MAIL ADDRESS:	
		STREET 1:		2701 KENT AVENUE
		CITY:			WEST LAFAYETTE
		STATE:			IN
		ZIP:			47906-1382
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2012136d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section&nbsp;13 or 15(d)&nbsp;of
the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
March 9, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>BIOANALYTICAL
SYSTEMS,&nbsp;INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified
in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Indiana</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>0-23357</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>35-1345024</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(State or other<BR>
jurisdiction of<BR>
incorporation or<BR>
organization)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(Commission File<BR>
Number)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(I.R.S. Employer<BR>
        Identification No.)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 48%; text-align: center"><FONT STYLE="font-size: 10pt"><B>2701 Kent Avenue<BR>
West Lafayette, Indiana</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 48%; text-align: center"><FONT STYLE="font-size: 10pt"><B>47906-1382</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(Address of principal executive offices)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: <B>(765) 463-4527</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 42.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form&nbsp;8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule&nbsp;425 under
the Securities Act (17 CFR 230.425)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule&nbsp;14a-12 under
the Exchange Act (17CFR240.14a-12)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under
the Exchange Act (17CFR240.14d-2(b))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under
the Exchange Act (17CFR240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section
12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; border-top: Black 1pt solid; border-left: Black 1pt solid; padding: 0.15pt 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Title of each class</FONT></TD>
    <TD STYLE="width: 33%; border-top: Black 1pt solid; padding: 0.15pt 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Trading Symbols</FONT></TD>
    <TD STYLE="width: 33%; border-top: Black 1pt solid; border-right: Black 1pt solid; padding: 0.15pt 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Name of exchange on which registered</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 0.15pt 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">Common Shares</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0.15pt 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">BASi</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 0.15pt 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">NASDAQ Capital Market</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company&#9;<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>







<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 7.01 Regulation FD Disclosure</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 9, 2020, the
Company issued the attached press release regarding Beth A. Taylor&rsquo;s election as Vice President &ndash; Finance and Chief
Financial Officer of the Company. The information furnished under Item 7.01 of this Current Report on Form 8-K and in Exhibit 99.1
attached hereto shall not be deemed &quot;filed&quot; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the &quot;<U>Exchange Act</U>&quot;), or incorporated by reference in any filing under the Securities Act of 1933, as amended,
or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01 Financial Statements and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d) Exhibits:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><A HREF="tm2012136d1_ex99-1.htm" STYLE="-sec-extract: exhibit">99.1</A>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<A HREF="tm2012136d1_ex99-1.htm" STYLE="-sec-extract: exhibit">Press Release, dated March 9, 2020.</A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 42.6pt">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Bioanalytical Systems,&nbsp;Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">Date: &nbsp;March 9, 2020</FONT></TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 47%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Robert Leasure, Jr.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Robert Leasure, Jr.&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2012136d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: right">&nbsp;<IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: right">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: left"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; color: #6C717A"><B>NEWS RELEASE</B></P>



<P STYLE="margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: left"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><B>FOR MORE INFORMATION:</B></TD>
    <TD STYLE="width: 40%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><B>Company Contact:</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">William Pitchford</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">Chief Human Resources Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">Phone: 765.250.9603</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">bpitchford@inotivco.com</TD></TR>
</TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: left"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Bioanalytical Systems, Inc. d/b/a Inotiv
Appoints Beth A. Taylor as New Chief Financial Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">WEST LAFAYETTE, Ind., March 9, 2020 --&nbsp;Bioanalytical Systems,
Inc. (NASDAQ: BASI), operating as Inotiv (the &ldquo;Company&rdquo; or &ldquo;Inotiv&rdquo;), today announced the appointment of
Beth A. Taylor, CPA, as Vice President - Finance and Chief Financial Officer of the Company. Ms. Taylor succeeds Jill C. Blumhoff,
who had served as the Company&rsquo;s Vice President - Finance and Chief Financial Officer since May 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ms. Taylor joins the Company with an extensive background in
corporate and operational finance and accounting, including as Vice President of Finance and Chief Accounting Officer for Endocyte,
Inc. Ms. Taylor possesses exceptional experience and expertise in business planning, technical accounting, compliance, and investor
relations for public companies, and a successful track record of cultivating support and relationships within organizations to
achieve goals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;I am pleased to welcome Beth to our team and look forward
to her contributions in driving our shared vision for growth and success,&rdquo; said Company President and Chief Executive Officer
Robert Leasure, Jr. &ldquo;Beth has the experience and business acumen necessary to lead the Company&rsquo;s financial and accounting
team with the goal of continuing to increase confidence and shareholder value for our evolving Company. I would also like to thank
Jill Blumhoff for her hard work and dedication to the Company and wish her well in her future endeavors,&rdquo; concluded Mr. Leasure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;It is a very exciting time to be joining Inotiv, with
the recent growth and investment in internal operations and through strategic acquisitions to better serve and grow our client
base through an increased scope of services,&rdquo; said Ms. Taylor. &ldquo;I am eager to join the Inotiv team and assist with
strategic growth iniatives. I look forward to contributing to the team&rsquo;s effort towards making investments to deliver excellent
experiences to our clients, and ultimately to drive long-term shareholder value.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Prior to joining Inotiv, Ms. Taylor held progressively responsible
VP of Finance, Controllership and other financial leadership positions at Endocyte, Inc., Author Solutions, Inc., Harlan Laboratories,
Inc., Republic Airways Holdings and Rolls-Royce Corporation. Ms. Taylor started her career in audit with Deloitte &amp; Touche
and received her B.S. in Accounting from Indiana University&rsquo;s Kelly School of Business in Bloomington, Indiana.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><IMG SRC="footer.jpg" ALT="">&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About the Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Bioanalytical Systems, Inc., operating
as Inotiv, is a pharmaceutical development company providing contract research services and monitoring instruments to emerging
pharmaceutical companies and the world's leading drug development companies and medical research organizations. The Company focuses
on developing innovative services supporting its clients&rsquo; discovery and development objectives for improved decision-making
and accelerated goal attainment. The Company&rsquo;s products focus on increasing efficiency, improving data, and reducing the
cost of taking new drugs to market. Visit <U>inotivco.com</U>&nbsp; for more information about the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This release may contain forward-looking
statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes
in the market and demand for our products and services, the development, marketing and sales of products and services, changes
in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business
and financial impact thereof, and various market and operating risks, including those detailed in the Company's filings with the
U.S. Securities and Exchange Commission.</I></P>



<P STYLE="margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="footer.jpg" ALT="">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: left"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: left"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !% (H# 2(  A$! Q$!_\0
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MV<@_3UJ7))<S=D-1;=D3T4R*6.>)98G#HPR&!X-/IIIJZ$U;1A1113 ****
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HIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>footer.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 footer.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  F RX# 2(  A$! Q$!_\0
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M*K2Y/06BD+J!DL,>N:-P..1STK8R%HHSSBDR/4=<4 +1110 449%% !1110
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M>M "T444 ,>6./&^15S_ 'CBF_:8/^>\?_?8K%N%AWZC<3JC.DB*K2)OP..
M/QJ"+RUD!FL"\?=5L""?QS7#+%R4K67X]VOT.R.&35[O\.USH?M,'_/>/_OL
M4]75QE&##U!S7-R- N]A8[$SD%[$_*/<YJ_9+'#K3) JI$]HLA51@$[CSBJI
MXJ4I)-+\?/OZ$SPZC&^OX>7^9KT49&<45V'*%%% (/2@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **SO[5
M;_H'7_\ WZ'^-']JM_T#K_\ []#_ !K'V]/O^#_R-?8S[?E_F:-%9W]JM_T#
MK_\ []#_ !H_M5O^@=?_ /?H?XT>WI]_P?\ D'L9]OR_S-&BL[^U6_Z!U_\
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M_P '_D'L9]OR_P S1HK._M5O^@=?_P#?H?XT?VJW_0.O_P#OT/\ &CV]/O\
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M<'#$C'# <@>I/!K5_M9_^@9?_P#?L?XT?VL__0,O_P#OV/\ &CV]/O\ @_\
M(/8U.WXK_,AT:]G,2PWKR--([F+?&58H .3D#N>N!6=<6%S<7+H@FA)U-I%E
M"GY?W(PWTW#^E:_]JMG/]F7V?7RA_C1_:S_] R__ ._8_P :/;T^_P"#_P @
M]C4[?BO\ROHHO5MM1DEMQ'<O<,RHQ(4ML4<'^[D=:RX+.[A?4S?::ET[K$R@
MYD627D C(''//]T"MS^UG_Z!E_\ ]^Q_C1_:S_\ 0,O_ /OV/\:/;T^_X/\
MR#V-3M^*_P S!U'1)+2WM;>U0SRB#RU7RF(5RV3(K#A#D]^P%3W5I.=7<M;S
M271F@:"Y"DJJ #?ST'\61WS6O_:S_P#0,O\ _OV/\:/[6?\ Z!E__P!^Q_C1
M[>GW_!_Y![&IV_%?YF5I=O>1:^TDL,C2.\OGR20\*N?DV/W!XX_PI=2CG5M9
MMEM9Y'O@OD,B$J?D"G)Z#!'>M3^UG_Z!E_\ ]^Q_C1_:S_\ 0,O_ /OV/\:/
M;T^_X/\ R#V-3M^*_P S-$8MM?>=;.68[F=W> [D 3^!^A4XQMZ\T[0HM0M;
MUC>0%%O$,S$,6Q)G)SQ\O# 8_P!FM#^UG_Z!E_\ ]^Q_C1_:S_\ 0,O_ /OV
M/\:/;T^_X/\ R#V-3M^*_P S2J.>%;B"2%_NNI4U1_M9_P#H&7__ '['^-']
MK/\ ] R__P"_8_QH=>DU9O\ !_Y J-1.Z7XK_,J*)W@3:/\ 3[ X*_\ /1?_
M *X_SS5JXNK34K!H$FB\R9/D1VY#=L_C52[NI9)DN;?3[V.Y3C+1##+Z'FK;
MVT-WILLC61AF<%B%4!]P]*Y(W?-".NG6^J];;VT?R9T2LN64M-?+3\=KZKYH
MDM+66&^FE<##Q(I8'[S 8)K+\3V\MQ)"%@=T$,@4K"91O.,# ^Z>N&[5=@U2
MX6!%GTZ]:4##,L8P3Z]:D_M9_P#H&7__ '['^-=%.K2C&R?GL^OR,9TZCE=K
M\5_F8<MI<F]RUI<?:V:V-O*<L(E 7>"W0?Q9]<U-%;3)K0?[-,+D7LDDEQM.
MUH"#@;N_\(QZBM;^UG_Z!E__ -^Q_C1_:S_] R__ ._8_P :OV]/O^#_ ,B?
M8U.WXK_,Q=:AFN]12>.UG8-'%Y/[DDGYLMAO^61QZU8:WU,>)H;F: ,C+*H>
M.0D*F!M&,8!ZGW)/I6E_:S_] R__ ._8_P :/[6?_H&7_P#W['^-'MZ??\'_
M )![&IV_%?YF9H$7]G/*D=O-]F*HOF26WER%\XP<#D#U/3UJ..'48=8N;F^L
M_-#VDGF&&1FW#/"KP,'&!CZFM?\ M9_^@9?_ /?L?XT?VL__ $#+_P#[]C_&
MCV]/O^#_ ,@]C4[?BO\ ,Q+2TN9;&X6SM_+$[*9K9E>%54#&U21R3_$1_6J\
MUG?/I6F">"79':D+$L/F_O>-N]2.,C\N:Z/^UG_Z!E__ -^Q_C1_:S_] R__
M ._8_P :/;T^_P"#_P @]C4[?BO\R];F0VT1E4))L&]5Z XY J2LW^UG_P"@
M9?\ _?L?XT?VL_\ T#+_ /[]C_&G]8I]_P '_D+V%3M^*_S,^<F6;4;;[/<N
M'E5M\*@X(P>YH:XOD4L\FI*HZDP1@#]:?+(7N'FBMM6@:3&\1HN"1WP32VT-
MY=73*9KZ*W"<F8 $MGI],5YUFY6C>_EZM^7XG==*-W:WG\O4BD:]EC:.0ZFR
M,,,/LZ<C\ZLV$GF:V?W,L6RT5 LH 8@-UXJ%A>0SRQRR:E( WR-"JD%?Q[U)
M:SBVE>9K/4YI6 7?)&"0/0<TX:33=]'K?ROZBGK!I6U73SMZ$FM?:EN+9[:-
MF*Q3G<J;BK;/E[<<_G5$RZS!$R^;<2AHH9'D\H;H\D[P@ Y( ''-:O\ :K?]
M Z__ ._0_P :/[5;_H'7_P#WZ'^->A[>GW_!_P"1Q^QGV_+_ #,I!J,TUA-+
M)>^1'=LH8QA7:,KP74#^]D9P.#GBF6K:M$EM;K'*B7+$%A&!Y&V1BQZ<;EQC
M/>MC^U6_Z!U__P!^A_C1_:K?] Z__P"_0_QH]O3[_@_\@]E/M^7^9F"YU;9>
M%?M1O 'VPF$>4HW<%6Q\QV].>35C3[N\ N WVJ:(E5MWN(=C%R"2" !A<@<D
M#K5O^U6_Z!U__P!^A_C1_:K?] Z__P"_0_QH]O3[_@_\@]C/M^7^9E)=:G]@
M+![XS%D^T;K<#RASN\L8^;MZ\<T+)J\XA0374<1:;$IA =D"@KN&."3D=!D5
MJ_VJW_0.O_\ OT/\:/[5;_H'7_\ WZ'^-'MZ??\ !_Y![&?;\O\ ,KZ1)J)N
ME^V/*Z2VD<QWQA0DA)RHP!T&.#6S6=_:K?\ 0.O_ /OT/\:/[5;_ *!U_P#]
M^A_C1[>GW_!_Y"]C/M^7^9HT5G?VJW_0.O\ _OT/\:/[5;_H'7__ 'Z'^-'M
MZ??\'_D'L9]OR_S-&BL[^U6_Z!U__P!^A_C1_:K?] Z__P"_0_QH]O3[_@_\
M@]C/M^7^9HT5G?VJW_0.O_\ OT/\:/[5;_H'7_\ WZ'^-'MZ??\ !_Y![&?;
M\O\ ,T:*SO[5;_H'7_\ WZ'^-']JM_T#K_\ []#_ !H]O3[_ (/_ "#V,^WY
M?YFC16=_:K?] Z__ ._0_P :/[5;_H'7_P#WZ'^-'MZ??\'_ )![&?;\O\S1
MHK._M5O^@=?_ /?H?XT?VJW_ $#K_P#[]#_&CV]/O^#_ ,@]C/M^7^9HT5G?
MVJW_ $#K_P#[]#_&C^U6_P"@=?\ _?H?XT>WI]_P?^0>QGV_+_,T:*SO[5;_
M *!U_P#]^A_C1_:K?] Z_P#^_0_QH]O3[_@_\@]C/M^7^9HT5G?VJW_0.O\
M_OT/\:/[5;_H'7__ 'Z'^-'MZ??\'_D'L9]OR_S-&BL[^U6_Z!U__P!^A_C1
M_:K?] Z__P"_0_QH]O3[_@_\@]C/M^7^9HT445L9!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
(0 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
